Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer
Author(s):
Giessen, C.; Stintzing, S.; Laubender, R. P.; Ankerst, D. P.; Schulz, C.; Moosmann, N.; Modest, D. P.; Schalhorn, A.; von Weikersthal, L. F.; Heinemann, V.